It has been reported by the UN-backed Medicine Patent Pool that up to 35 generic drugmakers around the globe will start making cost-effective versions of Pfizer Inc’s highly effective COVID-19 antiviral Paxlovid. This gesture is to ensure that the COVID-19 vaccination is available even in underdeveloped countries.
Statistics 17 Mar 22:— NCOC (@OfficialNcoc) March 17, 2022
Total Tests in Last 24 Hours: 38,595
Positive Cases: 514
Positivity %: 1.33%
Patients on Critical Care: 546
Pfizer has also signed a deal with a group of generic drugmakers. This deal was legalized last year when it was decided that global drug-making companies will aid in the development of cheap vaccination for 95 middle and low-income countries. The company has then been deciding the potential drugmakers that will be allocated with this task.
Paxlovid is an important COVID-19 inoculation that has proven its worth in fighting against this global pandemic. It has also reduced the hospitalizations of high-risk patients by around 90% in clinical trials.
All the 35 companies that will have the license will produce Paxlovid cover at least 12 different countries on the globe. These companies include some giant names in the pharmaceutical industry such as Israel’s Teva Pharmaceutical Industries, India-based Sun Pharmaceutical Industries, and US-based Viatris.
Out of the authorized companies 6 plan on developing the key ingredient for the drug, 9 plan to further convert the key ingredient into a finished pill. While the rest of the companies plan on doing both.
In the meantime, Pakistan’s positivity rate falls below 1% for the first time in 2022. Pakistan only reported two deaths in the span of the last 24 hours. The government officials are also considering life up the COVID-19 restrictions as the country is on a stable path to recover from this global pandemic.